Summary
Boston Scientific Corporation (BSX) has filed an 8-K report detailing a significant financing transaction. On March 3, 2022, the company, through its wholly-owned finance subsidiary AMS Europe B.V., entered into an Underwriting Agreement to issue €3,000,000,000 in aggregate principal amount of senior notes. These notes are divided into four tranches with varying interest rates and maturity dates, ranging from 2025 to 2034. The notes are fully and unconditionally guaranteed by Boston Scientific Corporation, indicating strong support for the debt issuance. The company announced on March 8, 2022, that the offering was completed, raising approximately €2.969 billion in net proceeds after fees. Boston Scientific intends to utilize these proceeds primarily to fund a tender offer for up to $2.5 billion of its existing senior notes, redeem specific outstanding senior notes (2022, 2023, and 2025 maturities) that are not purchased in the tender offer, and cover related interest, premiums, fees, and expenses. Any remaining funds will be allocated to other debt repayment and general corporate purposes. This move appears to be a strategic refinancing to manage its debt structure and potentially lower borrowing costs.
Key Highlights
- 1Boston Scientific Corp. (BSX) completed a €3 billion senior note offering through its subsidiary AMS Europe B.V.
- 2The offering consists of four tranches of senior notes with maturities in 2025, 2028, 2031, and 2034.
- 3The notes carry coupon rates ranging from 0.750% to 1.875%.
- 4The notes are fully and unconditionally guaranteed by Boston Scientific Corporation.
- 5Net proceeds from the offering amounted to approximately €2.969 billion.
- 6Proceeds will be used to fund a tender offer for up to $2.5 billion of existing senior notes and to redeem other specified senior notes.
- 7The refinancing aims to manage the company's debt obligations and potentially reduce interest expenses.